CAS: 89488-25-5; 5-Chloro-2-Hydroxyphenylboronic Acid

上下游产品

2-hydroxyphenyl boronic acid 5-chloro-2-methoxyphenyl boronic acid Trimethyl borate 1-chloro-4-(methoxymethoxy)benzene 4-chloro-2-(4-chloro-quinolin-2-yl)-phenol {(R)-2-[2-(5-chloro-2-hydroxy-phenyl)-pyrimidin-4-ylamino]-1-methyl-ethyl}-carbamic acid benzyl ester tert-Butyl 4-(4-(4-(2-chloro-4-(N-(2,4-dimethoxybenzyl)-N-(1,3,4-thiadiazol-2-yl)sulfamoyl)-5-fluorophenoxy)-4'-(trifluoromethyl)biphenyl-3-yl)pyridin-2-yl)piperazine-1-carboxylate 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-N-(ethoxymethyl)-2-fluoro-N-(5-fluoropyrimidin-2-yl)benzenesulfonamide

5-氯-2-甲氧基苯硼酸置于三溴化硼体系中,用 二氯甲烷 作为反应溶剂,化学反应 0.25H,反应生成 5-氯-2-羟基苯基硼酸
参考文献:Rh / Pd催化与手性和非手性配体:氮杂二氢二苯并xepines的多米诺合成.
标题:Rh / Pd催化与手性和非手性配体:氮杂二氢二苯并xepines的多米诺合成.
摘要:多米诺骨牌游戏:通过在单个锅中将rh催化的芳基化和pd催化的c-O偶联相结合,描述了合成氮杂二氢二苯并xepinepines的合成途径.首次实现了将手性和非手性配体结合到两组分,两种金属的转化中的能力,从而使产品具有中等至非常好的收率,并具有出色的对映选择性.
DOI:10.1002/anie.201303659

专利信息

专利号:US-2009076268-A1
优先权日:2007-09-14
标 题:Facile assembly of fused benzofuro-heterocycles
发明人：FITZGERALD ANNE E; LIU JING; MANI NEELAKANDHA S
权利人:FITZGERALD ANNE E; LIU JING; MANI NEELAKANDHA S
摘要:This invention concerns the synthesis of polycyclic structural components of pharmacological compounds, including the synthesis of fused benzofuro-heterocycles, through selective palladium-catalyzed cross-coupling and intramolecular cyclization.

专利号:US-11286268-B1
优先权日:2019-07-02
标题:EIF4E-inhibiting compounds and methods
发明人：SPERRY SAMUEL; XIANG ALAN X; ERNST JUSTIN T; REICH SIEGFRIED H; SPRENGELER PAUL A; SHAGHAFI MIKE; MICHELS THEO; NILEWSKI CHRISTIAN; TRAN CHINH VIET; PACKARD Garrick Kenneth; GRUBBS ALAN; URKALAN KAVERI; MUKAIYAMA TAKASUKE
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n n n n n n n n n n For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Q, L 1 , L 2 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.